First human test of sickle cell pill halted early
NCT ID NCT05660265
Summary
This was a very early, first-in-human study to check if a new oral drug called GSK4172239D was safe and how it moved through the body in people with sickle cell disease. Only 11 participants received a single dose of either the drug or a placebo. The study was terminated early, and its main goal was to gather initial safety data, not to treat the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Miami, Florida, 33155, United States
-
GSK Investigational Site
Tamarac, Florida, 33321, United States
-
GSK Investigational Site
Atlanta, Georgia, 30315, United States
-
GSK Investigational Site
Columbus, Georgia, 31904, United States
-
GSK Investigational Site
Riverdale, Georgia, 30274, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89113, United States
Conditions
Explore the condition pages connected to this study.